Clinical Trials Directory

Trials / Completed

CompletedNCT00194610

Botox as a Treatment for Interstitial Cystitis in Women

Botox (Botulinum Toxin A) as a Treatment for Interstitial Cystitis in Women: A Randomized Placebo Controlled Trial

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
20 (actual)
Sponsor
University of Washington · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

Patients with interstitial cystitis have been well documented to have pelvic floor muscle tenderness as well as pain on bladder distension. Some investigators have even suggested that pelvic floor muscle pain is primarily the cause of bladder problems. Botulinum toxin A causes muscle relaxation by inhibiting the acetylcholine release at the neuromuscular junction. It has been shown that this mechanism relieves pain in a number of muscle spasm-related syndromes. Because, at present, there is little effective therapy available for patients with interstitial cystitis, the researchers want to determine if botulinum toxin A will relieve bladder and pelvic pain in these patients.

Detailed description

Screening Visit: After being screened by her medical provider, the patient will be given the opportunity to ask questions about the study. She will then be asked to read and sign the consent and then be randomized. Then, for women of childbearing age, a pregnancy test will be done. Next, we will ask the patient to fill out baseline study forms and she will be given a Voiding Diary. She will also be asked to provide a urine sample which will be processed for chemistry and culture. Injection Visit: This visit will be scheduled one week after the Screening Visit. First, a standard history and physical will be done. Then the clinician will proceed with the injection. The subject will receive an injection of not more than 5 ml of 1% lidocaine without epinephrine at the site of the botulinum toxin A injection. Next, 25 units of Botox will be injected, via the transvaginal route, on either side of the bladder neck. The remaining 50 units will be injected (in 2 - 25 unit doses) into other pelvic sites that the patient has identified as tender during the patient examination. 1 Month Post Injection Mailing: The patient will be mailed a packet containing follow-up questionnaires and asked to mail them back upon completion. 6 Week Urine Collection Visit: Two weeks after receiving her study injection, we will ask the patient to go to the Urology Clinic and provide a urine sample. 2 Month Post Injection Mailing: Same as 1 Month Post Injection Visit. 3 Month Post Visit: The subject will be asked to fill out follow-up questionnaires and will be asked to turn in her last set of Voiding Diaries.

Conditions

Interventions

TypeNameDescription
DRUGBotoxBotox 25 international units per injection injected in two places in the bladder neck, with option to inject two other tender points with 25 units each
OTHERnormal salineNormal saline injected into the bladder neck via the perineum, 1 cc each given at positions 3 o'clock and 9 o'clock

Timeline

Start date
2004-05-01
Primary completion
2009-06-01
Completion
2010-09-01
First posted
2005-09-19
Last updated
2012-10-12
Results posted
2012-10-12

Source: ClinicalTrials.gov record NCT00194610. Inclusion in this directory is not an endorsement.